Outcome of Cervical Cancer Patients Treated with Concomitant Chemoradiation Followed by Moderate Dose Rate Brachytherapy
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2021
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901630380670976 |
|---|---|
| author | Rubina, Mukhtar |
| author_facet | Rubina, Mukhtar |
| contents | <p>Objectives: Cervical cancer is one of the common gynecological cancers that have high mortality and morbidity rate in developing countries because of late presentation due to lack of awareness programs and limited medical facilities. Brachytherapy is one of the modalities in its treatment. Much Data is available in the literature for Low Dose Rate (LDR) and High Dose Rate (HDR) Brachytherapy (BT) with little published data for Moderate Dose Rate (MDR) BT. Our objective of the study is to measure the Overall Survival (OS) and Disease-Free Survival (DFS) in patients of cervical cancer at different stages treated with concomitant chemoradiation followed by MDR-BT.</p> <p>Study design: It is a prospective observational study.</p> <p>Materials and Methods: This prospective study was conducted at MINAR cancer hospital, Multan, Pakistan. All biopsy has proven cervical cancer patients treated with concomitant chemoradiation followed by MDR-BT were included in the study to evaluate the outcome of treatment.</p> <p>Results: Cervical cancer patients 102 (87%) out of 117 with a stage from 1B-1V A completed their treatment as per plan. Mean follow-up was 4.16 years with an SD of 1.97. OS and DFS for five years was 68% and 80% as perusing Kaplan-Meier analysis. Hematological, bladder, and bowel toxicities were 9%, 28%, and 26%, respectively.</p> <p>Conclusion: Results of Concomitant chemoradiation (ERBT) followed by MDR-BT in terms of OS and DFS are comparable with LDR and HDR outcomes with acceptable radiation-induced toxicity. So is a reasonable choice for treating cervical cancer in cases where LDR or HDR is not available.</p> <p> </p> <div> <h2> Introduction</h2> </div> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18742061 |
| institution | Zenodo |
| language | |
| publishDate | 2021 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Outcome of Cervical Cancer Patients Treated with Concomitant Chemoradiation Followed by Moderate Dose Rate Brachytherapy Rubina, Mukhtar Brachytherapy Cervical cancer MDR Concomitant chemo radiation <p>Objectives: Cervical cancer is one of the common gynecological cancers that have high mortality and morbidity rate in developing countries because of late presentation due to lack of awareness programs and limited medical facilities. Brachytherapy is one of the modalities in its treatment. Much Data is available in the literature for Low Dose Rate (LDR) and High Dose Rate (HDR) Brachytherapy (BT) with little published data for Moderate Dose Rate (MDR) BT. Our objective of the study is to measure the Overall Survival (OS) and Disease-Free Survival (DFS) in patients of cervical cancer at different stages treated with concomitant chemoradiation followed by MDR-BT.</p> <p>Study design: It is a prospective observational study.</p> <p>Materials and Methods: This prospective study was conducted at MINAR cancer hospital, Multan, Pakistan. All biopsy has proven cervical cancer patients treated with concomitant chemoradiation followed by MDR-BT were included in the study to evaluate the outcome of treatment.</p> <p>Results: Cervical cancer patients 102 (87%) out of 117 with a stage from 1B-1V A completed their treatment as per plan. Mean follow-up was 4.16 years with an SD of 1.97. OS and DFS for five years was 68% and 80% as perusing Kaplan-Meier analysis. Hematological, bladder, and bowel toxicities were 9%, 28%, and 26%, respectively.</p> <p>Conclusion: Results of Concomitant chemoradiation (ERBT) followed by MDR-BT in terms of OS and DFS are comparable with LDR and HDR outcomes with acceptable radiation-induced toxicity. So is a reasonable choice for treating cervical cancer in cases where LDR or HDR is not available.</p> <p> </p> <div> <h2> Introduction</h2> </div> |
| title | Outcome of Cervical Cancer Patients Treated with Concomitant Chemoradiation Followed by Moderate Dose Rate Brachytherapy |
| topic | Brachytherapy Cervical cancer MDR Concomitant chemo radiation |
| url | https://doi.org/10.5281/zenodo.18742061 |